Accuri Cytometers, eBioscience announce worldwide co-marketing agreement

NewsGuard 100/100 Score

Accuri Cytometers, Inc., the fastest growing life sciences company marketing and producing revolutionary bench-top flow cytometer systems, and eBioscience, the number two supplier of research flow cytometry reagents, today announced that they have entered into a worldwide co-marketing agreement.  The collaboration is designed to offer scientists a better and more comprehensive solution for their flow cytometry research needs, harnessing the cost-effectiveness, ease-of-use, performance capabilities and accessibility of the Accuri C6 Flow Cytometer® System with the market leading extensive line of high quality cytometer research reagents offered by eBioscience.

Explicitly designed for routine use by biomedical researchers in their own labs, Accuri's full-featured bench-top cell analysis system provides powerful capabilities similar to industry-leading flow cytometers in a user-friendly format and at a fraction of the cost.  eBioscience, which is among the largest suppliers of flow cytometry research reagents worldwide, offers a wide range of high quality innovative flow cytometry research reagents optimized for a variety of applications.

"We are pleased to partner with reagent leader eBioscience to offer our growing customer base a wide range of quality reagents optimized for their varied research needs," said Jack Ball, Chief Commercial Officer of Accuri.  "The adoption of the Accuri C6 Flow Cytometer System by over 500 research labs for an increasing range of applications has brought the need for high quality reagents that work seamlessly with our systems to the fore.  This marketing partnership allows Accuri to further deliver on our promise to our customers to offer an affordable, easy-to-use flow cytometer solution—now made even more accessible with the easy availability of a full range of quality research reagents."

Accuri designed the C6 system from the ground up with input from hundreds of researchers.  Accuri's innovations, coupled with its state-of-the-art components, resulted in a cytometer that is powerful, robust, compact, easy-to-use and very affordable, at less than one-third the price of current market-leading flow cytometers and one-tenth the operating costs of the market leaders over five years of ownership.

The rapidly expanding eBioscience product range of over 11,000 innovative cell analysis products include eFluor® proprietary dyes and Nanocrystals, FlowCytomix™ Multiple Analyte Detection System, Platinum and INSTANT ELISA brands, creating an array of high performing solutions that enable comprehensive analysis of cells and soluble factors in the key areas of immunology and cell biology research.

"We are delighted to partner with Accuri, the fastest growing supplier of flow cytometers, and welcome the opportunity to educate our customers about the advantages of having a flow cytometer in their research labs, along with the outstanding performance attributes and surprising accessibility of the Accuri C6 Flow Cytometer system," said Tony Ward, Vice President of Commercial Operations of eBioscience.  "As part of our shared goal to make high performance cell analysis more accessible to researchers worldwide, this agreement will provide customers with an effective and comprehensive solution right out of the box."

Further terms of the agreement were not disclosed.

To learn more about the Accuri C6 Flow Cytometer System and eBioscience's line of flow cytometer research reagents, visit their booths and attend the Accuri workshops and tutorials at CYTO 2010 and IMMUNOLOGY 2010.

  • CYTO 2010 – May 8 – 12, 2010, Washington State Convention and Trade Center, Seattle, WA
    • Accuri Booths 113 and 212
    • eBioscience Booths 318-320

  • IMMUNOLOGY 2010™ – May 7 – 11, 2010, Baltimore Convention Center, Baltimore, MD
    • Accuri Booths 405 and, 504
    • eBioscience Booth 711

Source:

Accuri Cytometers, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New microfluidic device improves the separation of tumor cells and clusters from malignant effusions